Kairos Pharma to Host Key Opinion Leader Event on Phase 2 ENV105 Prostate Cancer Trial Results
TL;DR
Kairos Pharma's ENV105 shows promise in overcoming cancer drug resistance, potentially giving patients and investors an edge with its novel combination therapy approach.
ENV105 targets CD105 protein to reverse drug resistance, restoring effectiveness of standard cancer therapies through structural biology mechanisms in Phase 2 trials.
This breakthrough therapy could significantly improve prostate cancer treatment outcomes and quality of life for patients facing drug-resistant disease progression.
Kairos Pharma reveals interim Phase 2 results for ENV105, an antibody targeting cancer drug resistance through innovative CD105 protein inhibition technology.
Found this article helpful?
Share it with your network and spread the knowledge!
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced it will host a key opinion leader event on September 18, 2025, at 5 p.m. ET to discuss interim efficacy results from its Phase 2 trial of lead candidate ENV105 in advanced prostate cancer. The event will feature expert perspectives on the safety and efficacy findings from the ENV105 and apalutamide combination therapy, underscoring the compound's potential role in addressing cancer drug resistance.
The company's lead candidate, ENV105, is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer aimed at addressing significant unmet medical needs.
The upcoming KOL event represents a significant milestone for Kairos Pharma and the oncology community, as it will provide valuable insights into the clinical performance of ENV105 in combating drug-resistant prostate cancer. Prostate cancer remains one of the most common cancers among men worldwide, and the development of resistance to standard therapies poses a major challenge in treatment. The interim results could signal a breakthrough approach to overcoming treatment resistance and improving patient outcomes.
For investors and stakeholders following the company's progress, the latest news and updates relating to KAPA are available in the company's newsroom at https://ibn.fm/KAPA. The event's findings may have broader implications for the oncology drug development landscape, particularly in addressing mechanisms of drug resistance that limit the effectiveness of current cancer treatments across various malignancies.
Curated from InvestorBrandNetwork (IBN)
